Work

SLF1 polymorphism predicts response to oxaliplatin-based adjuvant chemotherapy in patients with colon cancer.

Year: 2021

Type: article

Abstract: mRNA, possibly leading to low SLF1 protein expression. We conclude that the rs6891545C > A polymorphism may serve as an independent marker of response to oxaliplatin-based adjuvant chemotherapy in patients with stage II and III colon cancer, with improved clinical benefit observed in patients with the A allele possibly attributable to low expression of SLF1 protein resulting in deficient DNA repair capacity.

Source: PubMed

Authors: Xiaohong Han, Zheng Wang, Lei Zhang, Yinchen Shen, Qiaoyun Tan, Yongkun Sun, Jianfei Wang, Xiaoyan Qian, Hongying Yang, Yuankai Shi

Institutions: Chinese Academy of Medical Sciences & Peking Union Medical College, Peking Union Medical College Hospital, Beijing Hospital, Cancer Hospital of Chinese Academy of Medical Sciences

Language: English

Topic: Genetic factors in colorectal cancer

Subfield: Pathology and Forensic Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

OpenAlex ID: W3157719596

FWCI: 0.438

Cites: 58

Cited by: 4

Related to: 10